FDA approves second brain imaging drug Vizamyl (flutemetamol F 18 injection)to help evaluate patients for Alzheimer’s disease, dementia

New Drug Approvals

  is the structure on right

Vizamyl (flutemetamol F 18 injection)

http://jnm.snmjournals.org/content/50/8/1251/F1.expansion.html get structure

 

Chemical name:	2-{3-[18F]fluoro-4-(methylamino)phenyl}-1,3-benzothiazol-6-ol    diagnostic aid
Cas Number	765922-62-1
INN  name	flutemetamol
Molecular Formula:

GE Healthcare

FDA PRESS RELEASE

For Immediate Release: Oct. 25, 2013

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm372261.htm

The U.S. Food and Drug Administration today approved Vizamyl (flutemetamol F 18 injection), a radioactive diagnostic drug for use with positron emission tomography (PET) imaging of the brain in adults being evaluated for Alzheimer’s disease (AD) and dementia.

Dementia is associated with diminishing brain functions such as memory, judgment, language and complex motor skills. The dementia caused by AD is associated with the accumulation in the brain of an abnormal protein called beta amyloid and damage or death of brain cells. However, beta amyloid can also be found in the brain of patients with other dementias and in elderly people without neurologic disease.

Vizamyl works by attaching to beta amyloid…

View original post 915 more words